DNA Methyltransferase Inhibitors in Combination with PARP inhibitors Generate Synthetic Lethality in BRCA-proficient Ovarian Cancer
Başlık:
DNA Methyltransferase Inhibitors in Combination with PARP inhibitors Generate Synthetic Lethality in BRCA-proficient Ovarian Cancer
Yazar:
Stojanovic, Lora, author.
ISBN:
9780438127531
Yazar Ek Girişi:
Fiziksel Tanımlama:
1 electronic resource (58 pages)
Genel Not:
Source: Masters Abstracts International, Volume: 57-06M(E).
Advisors: Feyruz V. Rassool Committee members: Rena Lapidus; Dana Roque.
Özet:
Approximately 10% of Epithelial ovarian cancer (EOC) patients have BRCA mutations and are treated with FDA approved poly (ADP-ribose) polymerase (PARP) inhibitors. While some patients with BRCA wild-type EOC have shown a response, the majority of BRCA mutated EOC respond to PARPi therapy. The standard therapy for EOC patients is platinum-based chemotherapy which often leads to resistance to this treatment. Therefore, new therapies are essential for the improvement of EOC treatment. In this study we will investigate the role of low-dose epigenetic therapy in reprograming the DSB repair response to potentially induce a "BRCAness" effect that sensitizes EOC cells to PARPi. We show that 5-AZA reprograms epigenome by changing the gene expression in DNA repair genes which lead to BRCAness and results in impaired HR-mediated repair. Lastly, we will determine whether the downregulation of FANCD2, is responsible for sensitization of EOC cell to PARPi therapy that results in increased cytotoxicity.
Notlar:
School code: 0373
Konu Başlığı:
Tüzel Kişi Ek Girişi:
Mevcut:*
Yer Numarası | Demirbaş Numarası | Shelf Location | Lokasyon / Statüsü / İade Tarihi |
---|---|---|---|
XX(693040.1) | 693040-1001 | Proquest E-Tez Koleksiyonu | Arıyor... |
On Order
Liste seç
Bunu varsayılan liste yap.
Öğeler başarıyla eklendi
Öğeler eklenirken hata oldu. Lütfen tekrar deneyiniz.
:
Select An Item
Data usage warning: You will receive one text message for each title you selected.
Standard text messaging rates apply.